Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,116 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,163)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05864534 | Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma | active not recruiting | Phase 2 | 25 | Northwestern UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05871021 | Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma(PRIDE) | active not recruiting | Phase 2 | 107 | University Hospital TuebingenOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05874921 | uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto(uTRACT) | recruiting | — | 450 | UroGen Pharma Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05877599 | A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | recruiting | Phase 1 | 45 | AstraZenecaINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05891171 | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers(ARC-25) | active not recruiting | Phase 1 | 40 | Arcus Biosciences, Inc.INDUSTRY | 3 | Sep 29, 2026 | clinicaltrials |
| NCT05902169 | Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM(SONOBIRD) | recruiting | Phase 3 | 560 | CarTheraINDUSTRY | 11 | Sep 29, 2026 | clinicaltrials |
| NCT05927142 | Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy(DURIPANC) | active not recruiting | Phase 1 / Phase 2 | 43 | Joachim Aerts, MD PhDOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05952024 | Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL(ACRUE) | recruiting | Phase 2 | 80 | AstraZenecaINDUSTRY | 5 | Sep 29, 2026 | clinicaltrials |
| NCT05987956 | Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms(Drugs-SNPs) | active not recruiting | Phase 2 / Phase 3 | 600 | Medicine Invention Design, IncINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06046794 | Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients(GemSign-01) | recruiting | N/A | 100 | Institut Paoli-CalmettesOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06093425 | Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma | not yet recruiting | Phase 3 | 820 | Transcenta Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 0 | Sep 29, 2026 | clinicaltrials |
| NCT06203600 | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | recruiting | Phase 2 / Phase 3 | 224 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06309225 | Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly((DACHOC-E)) | recruiting | N/A | 20 | Omar MahmoudOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06337318 | Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma | recruiting | Phase 3 | 600 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06377540 | MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma | recruiting | Phase 2 | 28 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06448754 | Volrustomig Priming Regimens Exploratory Phase II Platform Study(eVOLVE-01) | active not recruiting | Phase 2 | 194 | AstraZenecaINDUSTRY | 14 | Sep 29, 2026 | clinicaltrials |
| NCT06466434 | Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma | recruiting | N/A | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06479811 | [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers | recruiting | Phase 1 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06494241 | Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study | active not recruiting | — | 1,000 | AstraZenecaINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06498635 | Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial | recruiting | Phase 3 | 306 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06498648 | Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma | recruiting | Phase 1 / Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06498661 | Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)(SHIP-A-S01) | active not recruiting | N/A | 750 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 | clinicaltrials |
| NCT06524583 | Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour(L-UteCIN) | recruiting | Phase 2 | 198 | UNICANCEROTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06541210 | Building Community Living Labs in Black Communities to Advance Prostate Health Equity and Reduce Prostate Cancer Disparities in Black Men(CoLLab) | recruiting | N/A | 250 | Mayo ClinicOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06605664 | Hyperpolarized 13C-MRI in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy, Atezolizumab, and Bevacizumab | recruiting | Phase 2 | 45 | Chang Gung Memorial HospitalOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06608927 | Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma(PRISM-1) | active not recruiting | Phase 3 | 610 | Arcus Biosciences, Inc.INDUSTRY | 13 | Sep 29, 2026 | clinicaltrials |
| NCT06627712 | SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC | recruiting | Phase 3 | 318 | West China HospitalOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06637150 | Dalpicilib-Enhanced vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer | recruiting | Phase 3 | 1,388 | Fudan UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06649812 | Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma | recruiting | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06667687 | Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma | active not recruiting | Phase 1 | 21 | AbbVieINDUSTRY | 5 | Sep 29, 2026 | clinicaltrials |
| NCT06738303 | Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer(CATCH-177) | recruiting | Phase 2 | 44 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06763341 | A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06799065 | First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer | recruiting | Phase 1 / Phase 2 | 218 | Accent TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06865664 | FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma | recruiting | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06881784 | Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)(RASolve 301) | recruiting | Phase 3 | 590 | Revolution Medicines, Inc.INDUSTRY | 19 | Sep 29, 2026 | clinicaltrials |
| NCT06888921 | A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer(MAIA-ovarian) | recruiting | Phase 1 / Phase 2 | 60 | Compugen LtdINDUSTRY | 3 | Sep 29, 2026 | clinicaltrials |
| NCT06906471 | A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS | active not recruiting | Phase 1 / Phase 2 | 10 | Antelope Surgical Solutions, IncINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06943755 | Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors(STELLAR-311) | recruiting | Phase 2 / Phase 3 | 440 | ExelixisINDUSTRY | 17 | Sep 29, 2026 | clinicaltrials |
| NCT06977711 | Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL) | recruiting | Phase 1 | 10 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07011719 | Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma | recruiting | Phase 3 | 720 | Arcus Biosciences, Inc.INDUSTRY | 17 | Sep 29, 2026 | clinicaltrials |
| NCT07052305 | NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma | recruiting | Phase 1 | 24 | Washington University School of MedicineOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07100847 | Periprostatic Neurolysis in Prostate Cancer | active not recruiting | Phase 1 | 21 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07127874 | A Study of PHN-012 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 165 | Pheon TherapeuticsINDUSTRY | 3 | Sep 29, 2026 | clinicaltrials |
| NCT07140315 | DK222 Study at Hopkins | recruiting | Phase 1 | 6 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07185165 | An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.(ECLIPSE) | recruiting | Phase 2 | 81 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07195734 | Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer | recruiting | Phase 2 | 180 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07212491 | Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma | enrolling by invitation | — | 450 | Mayo ClinicOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07224425 | A Study of BI 3810944 in Patients With Advanced Cancer | recruiting | Phase 1 | 69 | Boehringer IngelheimINDUSTRY | 3 | Sep 29, 2026 | clinicaltrials |
Data updated 2 days agoSource updated Sep 29, 2026source: clinicaltrials